Clearmind Medicine Inc Dossier
Qualitative Analysis
Business overview
Clearmind Medicine Inc. (Nasdaq: CMND) is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, psychedelic-derived therapeutics. The company's primary objective is to research and develop proprietary compounds to address widespread and underserved health problems, with a core focus on binge behaviors and mental health challenges. Its flagship candidate is CMND-100, an oral therapeutic based on the proprietary compound MEAI (5-methoxy-2-aminoindane) designed to regulate binge behaviors, notably Alcohol Use Disorder (AUD). Clearmind's intellectual property portfolio is robust, consisting of 19 utility patent families with 32 granted patents globally.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of the company's lead non-hallucinogenic, MEAI-based oral drug candidate (CMND-100) through FDA-regulated Phase I/II trials at elite institutions including Yale School of Medicine and Johns Hopkins University.
Expected impact: Establish safety, tolerability, and early efficacy of MEAI to address the underserved global market for Alcohol Use Disorder.
Evaluating MEAI (CMND-100) as a combination and maintenance therapy alongside blockbuster GLP-1 medications like tirzepatide to address weight regain post-discontinuation.
Expected impact: Position the MEAI platform to capture a share of the rapidly growing global weight-loss and metabolic therapy market.
Aggressively filing and securing international patents for MEAI and its combination therapies across multiple jurisdictions (including recent filings in Japan and Hong Kong) targeting depression, obesity, and binge behaviors.
Expected impact: Protect the company's proprietary technology and build a robust, defensible portfolio of 19 patent families (including over 31 granted patents) to attract future out-licensing or M&A partners.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. This partnership funds preclinical studies evaluating MEAI in combination with tirzepatide for obesity, and provides Clearmind with exclusive licensing rights to key intellectual property developed at the Hebrew University.
Terms: Clearmind funds the preclinical studies and is obligated to pay Yissum royalties of 1.5% of net sales, alongside milestone payments and sublicense fees under their metabolic syndrome license agreement.
Medium. Collaborating on combination therapies pairing Clearmind's MEAI with NeuroThera's Palmitoylethanolamide (PEA) to target major depressive disorder and metabolic dysfunction-associated steatotic liver disease (MASLD).
Terms: The parties collaborate on patent filings (such as recent applications in Hong Kong and Israel). Under their broader cooperation framework with SciSparc, any future commercial joint venture would share economics on a 50%-50% basis.